ABL Bio's Series A Round

ABL Bio raised a round of funding on July 19, 2016.

ABL Bio (에이비엘바이오) is focused on developing bispecific antibody cancer programs. Its lead candidate, ABL001, is in a Korean Phase Ia/Ib trial to treat gastric cancer. ABL is also developi…

Articles about ABL Bio's Series A Round: